ASS1 and neoplasm: In summary, these results demonstrate that EVO is capable of suppressing the expression of the ASS1 protein via the Wnt/β-catenin/c-MYC signaling pathway, thereby suppressing arginine synthesis metabolism and tumor growth, while also activating the immune microenvironment of tumor cells.